News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
WKYC Earnings
This article provides a Q2 earnings snapshot for TherapeuticsMD. However, the content of the article is empty, indicating that specific financial details were not included or were unavailable at the time of extraction.
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
TherapeuticsMD (NASDAQ: TXMD) reported a significant decline in its Q2 2026 financial performance, with EPS dropping 80% to $0.01 and net income falling 70% to $164 thousand. This was primarily due to decreased license revenues and a modest increase in operating expenses. The company …
TherapeuticsMD, Inc. reported its Q2 2026 financial results, with revenue of $869K and diluted EPS of $0.01, showing a decrease from the prior year. The company has completed its transformation into a pharmaceutical royalty company, with revenue primarily derived from royalty and milestone payments …
TherapeuticsMD (TXMD) reported a decline in Q2 2026 license revenue to $869,000 from $952,000 in the prior year, with net income from continuing operations also falling to $164,000. The company's operating expenses were $1.7 million, and it held $9.2 million in cash and cash …
TherapeuticsMD (TXMD) reported its Q2 2026 financial results, revealing a net income of $164 thousand and license revenue of $869 thousand. The company has fully transitioned into a pharmaceutical royalty company, collecting royalties from licensees, and is actively exploring strategic alternatives including potential acquisition …
TherapeuticsMD (NASDAQ: TXMD) reported second-quarter 2026 financial results, with net income from continuing operations totaling $164 thousand. The company expects to recognize approximately $365K (CAD 500K) in revenue during the third quarter of 2026 from an IMVEXXY sales milestone achieved by Knight Therapeutics Inc. …
TherapeuticsMD (TXMD) experienced a decline in net income and license revenue in Q2 2026, alongside a slight increase in operating expenses. The company is actively exploring strategic alternatives due to ongoing risks from licensee performance, litigation, and market volatility. This information is based on …
This article is a placeholder with no content provided beyond the title. Therefore, no meaningful summary can be generated. The title suggests it would have been about TherapeuticsMD's second-quarter net income from continuing operations in the US.
Baslake Partners, LP, along with Baselake Management, LLC and David Paolella, has reported a beneficial ownership of 6.8% in TherapeuticsMD, Inc. common stock. This stake represents 790,703 shares, with shared voting and dispositive power among the reporting persons. The ownership percentage is based on …
TherapeuticsMD Inc. (TXMD) shares advanced 1.47% to $2.07 on Wednesday, outperforming a mixed trading session where the Dow Jones Industrial Average rose and the NASDAQ Composite Index fell. Despite the gain, the stock remains 29.83% below its 52-week high of $2.95, achieved on January …
The article provides a snapshot of TherapeuticsMD, Inc. (29TA.SG) stock performance as of August 7, 2026. It highlights the stock's price, recent news, and historical data. Key performance metrics like Year-To-Date and 1-Year trailing total returns are compared against the S&P 500 index.
This article from TradingKey provides an earnings forecast for TherapeuticsMD Inc (TXMD), focusing on future EPS and revenue growth estimates. It includes a snapshot of the company's current stock performance, market capitalization, and P/E ratio, alongside a comparison with peer companies in the pharmaceutical …
The article provides a financial health analysis of TherapeuticsMD Inc (TXMD), noting its current financial score of 8.46, ranking 48th in the Pharmaceuticals industry. The company shows a stable financial status and high operating efficiency, with significant year-over-year increases in quarterly revenue (84.22%) and …
This article provides a valuation analysis of TherapeuticsMD Inc (TXMD), noting its current valuation score of 7.89, ranking it 84th out of 155 in the Pharmaceuticals industry. It highlights the company's current P/E ratio of 130.46, which is below its recent high but significantly …
Despite a daily loss of 1.46%, TherapeuticsMD Inc. (TXMD) stock still outperformed competitors and closed at $2.03. This occurred on a positive trading day where the NASDAQ Composite Index and Dow Jones Industrial Average both saw significant gains. The stock is currently 31.19% below …
This article provides a detailed stock analysis of TherapeuticsMD Inc (TXMD), highlighting its healthy fundamentals, high growth potential, and fair valuation. While institutional ownership is very high, the stock is currently trading sideways. The company operates as a pharmaceutical royalty company, collecting royalties from …
This article analyzes the institutional confidence in TherapeuticsMD Inc (TXMD), noting its current institutional shareholding score of 3.00, placing it 92nd out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion has increased by 14.39% quarter-over-quarter to 32.99%. James Simons is identified as …
This article provides a revenue breakdown for TherapeuticsMD, Inc. (SWB:29TA), highlighting that the greatest contribution to its revenue comes from the United States. The company reported €1.53 million from the U.S. last year, an increase from €1.08 million the year prior. The data is …
This article provides a detailed income statement for TherapeuticsMD Inc (TXMD), offering both quarterly and annual financial data spanning several years. It includes key financial metrics such as total revenue, operating expenses, net income, and earnings per share, along with year-over-year comparisons. The page …
This article details the shareholder structure of TherapeuticsMD Inc (TXMD), outlining major shareholders and institutional holdings. It identifies key investment firms like Rubric Capital Management LP and Clearline Capital LP as top shareholders and provides a breakdown of shareholder types, including hedge funds, investment …
This article provides an overview of TherapeuticsMD Inc's (TXMD) dividend and stock split history. It indicates that the company has distributed no dividends in the past five years and lists several stock merger events that occurred on May 6, 2022, all with a 50→1 …
This article provides a revenue breakdown for TherapeuticsMD Inc (TXMD), focusing on regional contributions. As of the latest disclosed data, the United States accounts for 57.14% of revenue with $448.00K, and non-U.S. regions contribute 42.86% with $336.00K. The company has not yet disclosed relevant …
TherapeuticsMD Inc (TXMD) stock is currently priced at $2.06, with a market capitalization of $23.84M. The company, a pharmaceutical royalty firm, exhibits strong fundamentals and high growth potential, including a 132.10% average annual revenue growth over the past three years. Despite being considered fairly …
Shares of TherapeuticsMD Inc. (TXMD) fell 3.32% on Tuesday, closing at $2.04, despite a positive trading session for the broader market. This decline broke a three-day winning streak for the company's stock. The NASDAQ Composite Index and Dow Jones Industrial Average both saw gains …
Search by ticker symbol or company name and select a result to open its chart.